09.05 2025

AP Biosciences Featured in PharmaBoardroom Interview

Showcasing Vision for Innovative Antibody Drugs

08.28 2025

Australian Expert Dr. Morris Shares AP402 Trial Progress

AP Biosciences Strengthens Taiwan–Australia Clinical Collaboration

08.28 2025

AP Biosciences Invited AP402 PI, Australian Oncologist Dr. Morris Visits Taiwan

AP Biosciences Strengthens International Medical Collaboration

05.22 2025

[BioWorld] AP402 Clinical Trial Featured by Global News Outlet BioWorld

Exclusive interview with Dr. Jeng Her, CEO of AP Biosciences. AP402, targeting HER2-resistant tumors, is currently undergoing Phase I/II clinical trials in Australia.

04.30 2025

[Media Feature] AP402 Clinical Trial Featured by U.S. Patient Platform WhatNext

AP402, was recently featured in WhatNext, a trusted U.S.-based platform focused on cancer patient education and clinical trial awareness

04.29 2025

AP Biosciences Presents AP402 Preclinical Data at AACR

AP Biosciences Presents Preclinical Data on p95HER/CD137 T-Cell Engager at American Association of Cancer Research Annual Meeting

04.22 2025

FPD in Phase 1/2 Clinical Trials of AP402 for HER2+ Cancer Patients

AP Biosciences Doses First Patient in Phase 1/2 Clinical Trials of AP402 for HER2+ Cancer Patients

04.22 2025

AP Biosciences to Present New Preclinical Data at 2025 AACR Annual Meeting

Present new preclinical data for AP402, at the 2025 AACR Annual Meeting